rs121918695
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM2PP2PP3_StrongPP5_Very_Strong
The NM_001354712.2(THRB):c.947G>A(p.Arg316His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,878 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Exomes 𝑓: 6.8e-7 ( 0 hom. )
Consequence
THRB
NM_001354712.2 missense
NM_001354712.2 missense
Scores
14
4
1
Clinical Significance
Conservation
PhyloP100: 7.91
Genes affected
THRB (HGNC:11799): (thyroid hormone receptor beta) The protein encoded by this gene is a nuclear hormone receptor for triiodothyronine. It is one of the several receptors for thyroid hormone, and has been shown to mediate the biological activities of thyroid hormone. Knockout studies in mice suggest that the different receptors, while having certain extent of redundancy, may mediate different functions of thyroid hormone. Mutations in this gene are known to be a cause of generalized thyroid hormone resistance (GTHR), a syndrome characterized by goiter and high levels of circulating thyroid hormone (T3-T4), with normal or slightly elevated thyroid stimulating hormone (TSH). Several alternatively spliced transcript variants encoding the same protein have been observed for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 15 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), THRB. . Gene score misZ 2.5652 (greater than the threshold 3.09). Trascript score misZ 3.708 (greater than threshold 3.09). GenCC has associacion of gene with thyroid hormone resistance, generalized, autosomal dominant, resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta, thyroid hormone resistance, generalized, autosomal recessive.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.983
PP5
Variant 3-24127696-C-T is Pathogenic according to our data. Variant chr3-24127696-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 12555.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
THRB | NM_001354712.2 | c.947G>A | p.Arg316His | missense_variant | 10/11 | ENST00000646209.2 | NP_001341641.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
THRB | ENST00000646209.2 | c.947G>A | p.Arg316His | missense_variant | 10/11 | NM_001354712.2 | ENSP00000496686 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251446Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135894
GnomAD3 exomes
AF:
AC:
1
AN:
251446
Hom.:
AF XY:
AC XY:
1
AN XY:
135894
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461878Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 727242
GnomAD4 exome
AF:
AC:
1
AN:
1461878
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
727242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 09, 2021 | In the published literature, this variant has been reported in multiple families with either a pituitary or generalized resistance to thyroid hormone (RTH) including the healthy members implying a possible incomplete penetrance of this variant (PMIDs: 8381821 (1993), 8040303 (1994), 7593433 (1995), and 25040256 (2014)). In addition, functional studies have shown that this variant has a deleterious effect on THRB protein function (PMIDs: 8381821 (1993), 7838159 (1994)12554782 (2003), 21795843 (2012), and 25040256 (2014)). - |
Thyroid hormone resistance, generalized, autosomal dominant Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 08, 2022 | Variant summary: THRB c.947G>A (p.Arg316His) results in a non-conservative amino acid change located in the Nuclear hormone receptor, ligand-binding domain (IPR000536) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251446 control chromosomes. c.947G>A has been reported in the literature in individuals and co-segregating families affected with autosomal dominant generalized Thyroid Hormone Resistance (example, Dieu_2020, Adams_1994, Macchia_2014). These data indicate that the variant is likely to be associated with disease. Multiple publications report experimental evidence evaluating an impact on protein function (example, Adams_1994, Macchia_2014). The most pronounced variant effect results in <10% of normal affinity constant for T3 binding by receptors. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Selective pituitary resistance to thyroid hormone Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 1994 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;D;D;D;D;D;D;D;D;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
.;.;.;.;.;.;.;.;.;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;M;M;M;M;M;M;M;M;M;.
MutationTaster
Benign
A;A;A;A
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;D;.;.;.;.;.;.;D;.;D
REVEL
Pathogenic
Sift
Uncertain
D;D;.;.;.;.;.;.;D;.;D
Sift4G
Uncertain
D;D;.;.;.;.;.;.;D;.;D
Polyphen
D;D;D;D;D;D;D;D;D;D;.
Vest4
MutPred
Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);Gain of glycosylation at S314 (P = 0.1061);.;
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at